← FDA DRUG APPROVALS
FDA ANDA · ANDA203182
CISATRACURIUM
cisatracurium besylate
Sponsor: FRESENIUS KABI USA
APPLICATION
ANDA203182
TYPE
ANDA
ORIGINAL APPROVAL
2015-02-26
LATEST ACTION
2025-06-17
ROUTE
INTRAVENOUS, INJECTION
DOSAGE FORM
INJECTABLE
MARKETING STATUS
Prescription
Products
CISATRACURIUM BESYLATE PRESERVATIVE FREEPrescription
CISATRACURIUM BESYLATE EQ 2MG BASE/ML · INJECTABLE · INJECTION
CISATRACURIUM BESYLATE PRESERVATIVE FREEPrescription
CISATRACURIUM BESYLATE EQ 10MG BASE/ML · INJECTABLE · INJECTION
Approval history
2025-06-17Labeling · Supplement 11 · standardAP
2016-06-24Labeling · Supplement 1 · standardAP
2015-02-26UNKNOWN · OriginalAP
Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.
Weekly Briefing
Read a past issue →Get the Weekly GxP Briefing
Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.